The Canadian company Apotex has snapped up rights to five ophthalmic products from eyecare pharma player Harrow as part of an exclusive out-licensing agreement that will grant the Canadian player commercialization and development rights to assets at different stages of development in its country.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?